APA

Lang J. M., Kaikobad M. R., Wallace M., Staab M. J., Horvath D. L., Wilding G., Liu G., Eickhoff J. C., McNeel D. G. & Malkovsky M. (20111102). Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. : Cancer immunology, immunotherapy : CII.

Chicago

Lang Joshua M, Kaikobad Mahazarin R, Wallace Marianne, Staab Mary Jane, Horvath Dorothea L, Wilding George, Liu Glenn, Eickhoff Jens C, McNeel Douglas G and Malkovsky Miroslav. 20111102. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. : Cancer immunology, immunotherapy : CII.

Harvard

Lang J. M., Kaikobad M. R., Wallace M., Staab M. J., Horvath D. L., Wilding G., Liu G., Eickhoff J. C., McNeel D. G. and Malkovsky M. (20111102). Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. : Cancer immunology, immunotherapy : CII.

MLA

Lang Joshua M, Kaikobad Mahazarin R, Wallace Marianne, Staab Mary Jane, Horvath Dorothea L, Wilding George, Liu Glenn, Eickhoff Jens C, McNeel Douglas G and Malkovsky Miroslav. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. : Cancer immunology, immunotherapy : CII. 20111102.